[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"risk-behavior\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:risk-behavior":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,60,94,119,157,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100612570","follow-up-study-of-varapodio-trial-effect-of-longevity-and-fasting-mimicking-diet-on-risk-factors-age-correlated-and-biomarkers-of-aging-100612570",false,"NCT07255300","Follow up Study of Varapodio Trial: Effect of Longevity and Fasting Mimicking Diet on Risk Factors Age Correlated and Biomarkers of Aging","Follow up Study of the Effects of the Longevity and the Fasting Mimicking Diet on Body Composition, Age-related Risk Factors and Biomarkers of Aging in a Randomized Study 1 and 2","Inclusion Criteria:\n\nSubjects of 30-65 years of age;\n\nExclusion Criteria:\n\nindividuals with a family member already included in the study; individuals who are allergic to tree nuts (macadamia, cashew, almond, pecan), soy, oats, sesame, or celery\u002Fceleriac; pregnant females; Individuals with any documented cancer diagnosis within the past 5 years; documented myocardial infarction within past 5 years; documented cerebrovascular accident within past 5 years; chronic steroid use (longer than 45 consecutive days); insulin-dependent diabetes mellitus; individuals taking insulin or insulin-like drugs and individuals taking hypoglycemic agents other than metformin. In this last case, close attention will therefore be paid to the self-monitoring of blood glucose during the FMD cycles; Individuals with severe hypertension (systolic greater than 200 mmHg and or diastolic greater than 105 mmHg.\n\nChange in prescription medications, over-the-counter (OTC) medications, medical foods, and nutritional supplements within 30 days prior to the start and for the duration of the study.\n\nUse of medications classified as narcotics 15 days prior start and for the duration of the study.\n\nUse of prescription medications and\u002For over-the-counter medications for acute and semi- acute medical conditions 15 days prior to start and for the duration of the study.\n\nUse of acetaminophen is permitted on an as-needed basis. Use of an investigational drug or participation in an investigational study within 30 days prior to the start and for the duration of the study.\n\nUse of oral or injectable corticosteroids within 30 days prior to the start and for the duration of the study.\n\nUse of anticoagulant medications (heparin compounds or warfarin) within 30 days prior to the start and for the duration of the study. Use of aspirin 81 mg or 325 mg once daily is permitted.\n\nUse of neuroactive prescription medications including major and atypical antipsychotic medications, anti-depressants, anti-anxiolytics, and epilepsy medications within 30 days prior to the start and for the duration of the study.\n\n(subjects will not be allowed to discontinue prohibited prescription medications to meet enrolment criteria).\n\nA history of allergy or intolerance to study products. Detailed descriptions of study product are included in Section 4.1 and 4.2, appended to the Study Informed Consent.\n\nClinically significant vital sign abnormalities (systolic blood pressure \\\u003C90 mmHg or \\>200 mmHg, diastolic blood pressure \\\u003C50 mmHg or \\>105 mmHg or resting heart rate of \\\u003C50 or \\>100 bpm) at screening visit.\n\nA serious, unstable illness including cardiac, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, immunologic, or hematologic disease.\n\nKnown infection with HIV, TB or Hepatitis B or C.\n\nA current diagnosis or personal history of:\n\nAny cardiovascular disease including myocardial infarction, angina, cardiovascular surgery (within 5 years), congestive heart failure, cardiac arrhythmias or conduction abnormalities, cerebrovascular accident, transient ischemic attack (TIA), or peripheral vascular disease, deep vein thrombosis or pulmonary embolus. Diabetes mellitus requiring inhaled or injected insulin.\n\nAny autoimmune disease such as inflammatory bowel disease (including Crohn's disease and\u002For ulcerative colitis), multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, polymyositis, scleroderma and\u002For thyroiditis.\n\nAny significant liver or kidney disease such as cirrhosis or non-alcoholic fatty liver disease, glomerulonephritis, and\u002For ongoing dialysis treatment.\n\nAny malignancy (with the exception of adequately treated malignancies with no known recurrence for \\>2 years).\n\nAny serious mental illness including a history of attempted suicide. Any medical condition that in the opinion of the primary care doctor or a specialist would preclude safe participation in this study or interfere with compliance.\n\nUse of drugs of abuse (such as marijuana, cocaine, phencyclidine \\[PCP\\] and methamphetamine) 15 days prior to Day 1 and for the duration of the study.\n\nHistory of regular intake of \\>14 alcoholic drinks per week for females, and \\>21 drinks per week for males (1 drink = 35 cl. beer, 12 cl. wine, or 30 ml. hard liquor).\n\nTechnical reasons\n\nAny condition in which bioelectrical impedance testing would be impossible or uninterpretable (e.g. prostheses in extremities on both sides, limb amputation, implanted pacemaker, inability to lay still or supine, or skin defects on preferred electrode placement sites.\n\nOther Exclusion Criteria: Inability to comply with study and\u002For follow-up visits.\n\nAny concurrent condition (including clinically significant abnormalities in medical history, physical examination or laboratory evaluations) which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.\n\nAny sound medical, psychiatric and\u002For social reason which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.\n\nAbnormal laboratory findings including: abnormal blood counts (hematocrit \\\u003C 33% or \\> 47%; WBC \\\u003C 3.0 or \\> 12.0 x10\\^3\u002Fmm3; platelets \\\u003C 140 or \\> 500 x 10\\^9\u002FL); abnormal kidney function test (creatinine \\> 2.5 mg\u002FdL) or liver function test(s) (AST, ALT, alkaline phosphatase) \\> 1.5X the upper limit of normal; serum calcium \\> 11 mg\u002FdL); serum K \\\u003C 3.5 mEq\u002FL; Na \\\u003C 134 or \\> 148 mmolL-1 Women of Childbearing Potential Contraception: the effects of the study products on the developing human fetus have not been studied extensively. For this reason, women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential will have a pregnancy test prior to receiving study products. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform study staff and her primary care physician immediately.\n\nPregnancy: because there is an unknown but potential risk for adverse events in pregnant women during treatment with the study products, pregnant women are not eligible for study participation.\n\nBreast-feeding: Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study products, breastfeeding mothers are not eligible for study participation.",true,"ALL",{"count":19,"type":20},135,"ESTIMATED","INTERVENTIONAL",[23],"NA","A large ongoing randomized, open-label trial aimed at evaluating the effects of two different dietary interventions, FMD and LD, on body composition and cardiovascular (CV) biomarkers in a real word population (NCT05698654) is actually ongoing. This trial started in January 2024 will enrol 501 adult subjects between the ages of 30 and 65: 167 subjects randomized to the FMD arm with a 5-day meal program once every three months for a 6-month period (arm 1); 167 subjects randomized to follow the FMD plus a Longevity Diet program (FMD+LD) for a 6-month period (arm 2); 167 randomized to the control group (arm 3) that will continue their usual diet. On 2024,410, participants were enrolled and randomly assigned to FMD, FMD + LD, or control arm. Although preliminary data demonstrated the beneficial effects of such nutritional plans on body weight, BMI, body composition, and cardiovascular (CV) biomarkers, limited data is available on the long-term effects of these powerful nutritional interventions.",[26,27,28,29,30,31,32],"Fat Mass","Risk Factors Cardiovascular Disease","Epigenetic Aging","Metabolism Changes","Overweight (BMI > 25)","Risk Behavior","Obesity (Disorder)",[34,35,36,37,38,39,40,41,42,43,44,45,46,26],"fasting","fasting mimicking diet","Longevity Diet","Longevity","Diet","Aging","FMD","Nutrition","Diseases","LD","Clinical Trial","Randomized","Health","RECRUITING","2025-11-20",{"date":50,"type":51},"2025-12-01","ACTUAL",{"date":53,"type":51},"2025-05-02",{"date":55,"type":20},"2027-06-02",{"name":57,"class":58},"Fondazione Valter Longo","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":72,"conditions":73,"keywords":79,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100540053","building-social-and-structural-connections-for-the-prevention-of-opioid-use-disorder-among-youth-experiencing-homelessness-100540053","NCT06311838","Building Social and Structural Connections for the Prevention of Opioid Use Disorder Among Youth Experiencing Homelessness","Building Social and Structural Connections for the Prevention of Opioid Use Disorder Among Youth Experiencing Homelessness: An RCT Examining Biopsychosocial Mechanisms","Inclusion Criteria:\n\n* Youth must meet the criteria for homelessness as defined by the McKinney-Vento Act: children and youth who lack a fixed, regular, and adequate nighttime residence; or live in a welfare hotel, or place without regular sleeping accommodations, or live in a shared residence with other persons due to the loss of one's housing or economic hardship\n* Must speak english adequately to complete measures\n\nExclusion Criteria:\n\n* Youth who have a stable housing situation.\n* Non-English speaker","14 Years","24 Years",{"count":70,"type":20},300,[23],"Homelessness severely affects health and well-being and is particularly negative for youth. Between 70-95% of youth experiencing homelessness (YEH) report problem substance use and 66-89% have a mental health disorder. Youth appear to be at greater risk for living on the streets or being homeless than adults and are more vulnerable to long term consequences of homelessness. Multiple social determinants of health (SDOH) are uniquely associated with homelessness, driving substance use and adverse mental health consequences. However, limited research has identified pragmatic interventions that have a long-term ameliorating impact on the complex, multi-symptomatic issues among these youth. This study overcomes prior gaps in research through testing a multi-component comprehensive prevention intervention targeting SDOH that may affect biopsychosocial health indicators and longer-term health outcomes. In partnership with a drop-in center for YEH, youth between the ages of 14 to 24 years, will be engaged and randomly assigned to conditions using a dismantling design so that essential intervention components can be efficiently identified. In particular, youth (N = 300) will be randomly assigned to a) Motivational Interviewing\u002FCommunity Reinforcement Approach + Services as Usual (MI\u002FCRA + SAU, n = 80), b) Strengths-Based Outreach and Advocacy + Services As Usual (SBOA + SAU, n = 80), c) MI\u002FCRA + SBOA + SAU (n = 80) or d) SAU (n=60) through the drop-in center. In order to assess the longer-term prevention effects on substance use, mental health and other outcomes, all youth will be assessed at baseline and at 3, 6, 12, 18 and 24-months post-baseline. The primary goal of this study is to establish the impact of a comprehensive intervention embedded within a system that serves YEH, a community drop-in center, on youth's opioid misuse and disorder, other substance misuse and disorders, mental health diagnoses, and other targeted outcomes. This study will offer unique information on the physiological and psychological stress pathways underlying change for specific subgroups of youth along with cost estimates to inform future implementation efforts in drop-in centers around the country.",[74,75,76,77,31,78],"Opioid Use Disorder","Dual Diagnosis","Housing Problems","Mental Disorder in Adolescence","Homelessness",[80,81,82,83],"youth experiencing homelessness","social determinants of health","opioid use disorder","substance use","2025-09-18",{"date":86,"type":51},"2025-09-22",{"date":88,"type":51},"2024-05-06",{"date":90,"type":20},"2029-12-01",{"name":92,"class":58},"Ohio State University",2,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":59},"100479412","detection-of-risk-behaviors-pilot-observational-study-with-bedridden-and-agitated-patients-100479412","NCT05522647","Detection of Risk Behaviors: Pilot Observational Study With Bedridden and Agitated Patients.","DECORIPAA","Inclusion Criteria:\n\n* Hospitalized in the Neurosurgery Department of the Clermont-Ferrand University Hospital\n* Suffering from neurological and\u002For cognitive disorders leading to agitation and\u002For confusion\n* Affiliation to a social security system\n* Hospitalization in the department for at least 9 days\n* Acceptance by the patient and\u002For trusted person capable of giving informed consent to participate in the research\n\nExclusion Criteria:\n\n* Acute or transient agitation phase of somatic origin (bladder globe, pain, ionic disorder...)\n* Patient under guardianship, curatorship or safeguard of justice\n* Pregnant and breastfeeding women\n* Refusal to participate","18 Years",{"count":103,"type":20},20,"OBSERVATIONAL","There is a risk of falls and injuries in bedridden hospitalized patients, increased in agitated or confused patients. In neurosurgery departments, brain damaged patients can present a loss of consciousness of risky behaviors and be in a state of agitation which frequently leads to their endangerment. The repercussions of this endangerment are multiple. For the patients, there may be a feeling of insecurity, with physical or chemical restraint solutions which deprive them of their freedom without a total guarantee of safety. For the caregivers, there is an emotional distress in front of this endangerment, and a professional guilt. Finally, there are economic repercussions due to the costs of complementary examinations and the lengthening of hospitalization.\n\nThe objective of the present study is to determine the nature and frequency of occurrence of risk behaviours, through the observation of bedridden and agitated hospitalized patients. These risk behaviours are defined as potentially dangerous and are warning signs for the caregiver. A better understanding of these behaviours could help to better anticipate falls and injuries and to implement preventive measures more quickly.",[31,107,108,109],"Agitation","Hospitalization","Bedridden Patients","2025-07-10",{"date":112,"type":51},"2025-07-14",{"date":114,"type":51},"2025-07-09",{"date":116,"type":20},"2026-07-31",{"name":118,"class":58},"University Hospital, Clermont-Ferrand",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":101,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":139,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":93},"100524217","neurobehavioral-profiles-of-adaptive-stress-responses-in-individuals-with-alcohol-use-disorder-100524217","NCT06105853","Neurobehavioral Profiles of Adaptive Stress Responses in Individuals With Alcohol Use Disorder","Towards Neurobehavioral Profiles and Models of Adaptive Stress Responses and Resilience in Individuals With Alcohol Use Disorder","A03","Inclusion criteria are:\n\n* age between 16 and 65 years\n* meeting at least 2 criteria of an alcohol use disorder according to the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5), yet without the need for a therapeutic intervention\n* fluency in German\n* able to understand the study procedures and give informed consent\n* willingness to use a study smartphone\n\nExclusion criteria are:\n\n* current use of drugs or medications that interact with the central nervous system or the glucocorticoid system\n* contraindications for magnetic resonance imaging\n* medical history of bipolar disorder, psychotic disorder, schizophrenia or schizophrenic spectrum disorder, or substance use disorder other than alcohol, nicotine, or cannabis\n* medical history of severe head injury or other severe central nervous system disorders or other severe somatic disorders (e.g. liver cirrhosis)\n* pregnancy","65 Years",{"count":129,"type":20},100,[23],"The goal of this observational study is to investigate longitudinal stress response profiles and adaptive versus non-adaptive stress responses in alcohol use disorder. The main questions the projects aims to answer are:\n\nWhat are the neurobehavioral underpinnings of adaptive stress responses and resilience to repeated stress exposure with regards to:\n\n* alcohol craving?\n* alcohol use?\n* their modulation by prior stress exposure, social interactions, coping strategies and individual health behavior?\n\nParticipants will:\n\n* be exposed to an established experimental stress-induction protocol, the Trier Social Stress Test\n* be exposed to their favorite drink in a bar lab environment\n* be assessed using fMRI to determine their neural alcohol cue reactivity, response inhibition, and emotion processing\n* conduct an ambulatory phase to assess stressors, alcohol craving, substance use and details on social interactions, health behavior and coping strategies using ecological momentary assessment tools.",[133,134,135,136,137,138,31],"Alcohol Use Disorder","Stress Reaction","Social Stress","Craving","Relapse","Addiction, Alcohol",[140,141,142,143,144,145,146,147],"stress","resilience","craving","sensitization","habituation","cortisol","ecological momentary assessment","alcohol use disorder","2025-04-28",{"date":150,"type":51},"2025-04-29",{"date":152,"type":51},"2023-12-01",{"date":154,"type":20},"2027-06-30",{"name":156,"class":58},"Central Institute of Mental Health, Mannheim",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":16,"sex":17,"minAge":101,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":93},"100483539","trac-er-intervention-to-reduce-risky-alcohol-use-and-hiv-risk-100483539","NCT05576350","TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk","Evaluation of a Combined Motivational Interviewing and Ecological Momentary Intervention to Reduce Risky Alcohol Use Among Individuals Vulnerable to HIV\u002FAIDS","TRAC-ER","Inclusion Criteria:\n\n* is between the ages of 18-35 at the start of the study\n* owns a smartphone\n* has not been diagnosed with HIV\n* screens positively for at-risk alcohol use (score of 4 or higher on the AUDIT-C, OR report engaging in binge drinking at least once over the past 12 months).\n* meets criteria for pre-exposure prophylaxis (PrEP) OR is identified as being at high risk for HIV (i.e., reports history of using PrEP\u002FPEP, reports unprotected sex, etc.)\n\nExclusion Criteria:\n\n* do not speak English\n* are actively detoxifying from substances and need medical supervision\n* a score of 20 or greater on the Alcohol Use Disorders Identification Test","35 Years",{"count":167,"type":20},405,[23],"Ecological momentary interventions (EMI), which use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events, can help to address triggers in real-time. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use. A mobile app has been developed that uses GPS tracking to determine when individuals visit \"risky\" places and then delivers a survey asking what behaviors they engaged in while at the location.\n\nThe goal of the proposed study is to use this app to enhance the Tracking and Reducing Alcohol Consumption (TRAC) intervention by delivering messages that encourage participants to employ strategies discussed during TRAC sessions when arriving at risky places. When they leave these places, they will complete a survey and breathalyzer reading in order to collect event-level self-report and biological data on alcohol use and HIV risk. If their breathalyzer result indicates alcohol use, they will receive harm reduction messaging. It is expected that combining TRAC with EMI (\"TRAC-ER\") will increase effectiveness by reinforcing topics discussed during these sessions, providing in-the-moment messaging to address triggers, and collecting real-time alcohol use data.",[31,133,171],"HIV Infections",[173,174,175,176,177,178,179],"motivational interviewing","behavior","ecological momentary intervention","EMI","TRAC","mobile","GPS","2025-03-25",{"date":182,"type":51},"2025-03-30",{"date":184,"type":51},"2024-12-09",{"date":186,"type":20},"2027-05",{"name":188,"class":58},"University of Kentucky",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":196,"minAge":4,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":199,"conditions":200,"keywords":203,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":59},"100568405","molecular-classification-in-relation-to-prevention-of-endometrial-cancer-recurrence-and-lifestyle-factors-100568405","NCT06680791","Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle Factors","MPEC","Inclusion Criteria:\n\n* Clinical diagnosis of endometrial cancer.\n* Treated with uterine removal with adequate staging.\n\nExclusion Criteria:\n\n* There are no exclusion criteria in this study.","FEMALE",{"count":198,"type":20},280,"Endometrial cancer (EC) is one of the most prevalent cancers in women worldwide with a significantly increasing incidence, especially in developed countries. One of the reasons for the increase in the incidence of this disease is the rising incidence of obesity as the biggest risk factor for the development of this disease. Other important risk factors are hypertension, diabetes mellitus and the general ageing of the population. These risk factors are not only associated with a higher risk of developing the disease, but also, for example, with post-operative complications affecting the quality of life of patients after surgery. The molecular classification of endometrial cancer, which has been introduced into clinical practice in recent years, is currently helping physicians to make treatment decisions for individual patients and predict prognosis. In this project, we would like to focus on the relationship of this molecular classification with genomic mutational signatures detected by whole-exome sequencing and their association with lifestyle risk factors for endometrial cancer (obesity - BMI, hypertension, diabetes mellitus), including the extent of staging lymphadenectomy. Identification and detailed analysis of dominant mutational profiles associated with a specific molecular subtype of EC and their influence on the presence of lifestyle risk factors may have a major impact on both disease development and prevention of disease recurrence. The possible relationship of the mutational profile with the extent of staging lymphadenectomy may help in deciding the extent of this surgical procedure, which subsequently affects the quality of life of patients, especially in patients with high BMI. Given the widespread prevalence of lifestyle risk factors in the developed world, a detailed understanding of the relationship between the genetic profile, its alterations and the prevalence of these risk factors, with potentially major implications for treatment success, is crutial.",[201,202,31],"Endometrial Cancer","Genetic Predisposition",[204,205,206,207,208],"Endometrial cancer","BMI","Hypertension","Diabetes mellitus","Genetic predispositions","2024-11-06",{"date":211,"type":51},"2024-11-08",{"date":213,"type":51},"2024-07-15",{"date":215,"type":20},"2028-12",{"name":217,"class":218},"Lukas Vanek","OTHER_GOV"]